Probiotics for Primary Hyperoxaluria

Probiotics have not been shown to help primary hyperoxaluria (PH), a rare inherited liver enzyme disorder in which the body makes too much oxalate. Researchers hoped Oxalobacter formigenes, a gut bacterium that lives on oxalate, could clear some of that excess through the gut, and tested it as an investigational freeze-dried capsule called Oxabact. In four double-blind, placebo-controlled trials lasting 8 to 52 weeks, it did not lower urinary or plasma oxalate significantly more than placebo (Hoppe 2011; Hoppe 2017; Milliner 2018; Ariceta 2023), and a 2025 meta-analysis of five randomised trials with 208 patients concluded it was ineffective (Khan 2025).

The trials were small, because PH is rare, and all tested formulations of the same product, so a modest effect can't be fully ruled out: in the longest trial, plasma oxalate drifted down on Oxabact and up on placebo, but the difference was not significant (p = 0.064) (Ariceta 2023). Treatments that do lower oxalate exist. The RNA interference drug lumasiran cut urinary oxalate by 65.4% in PH type 1 (Garrelfs 2021). A probiotic is not a substitute for them.

Oxalobacter formigenes relies solely on oxalate for growth (Daniel 2021). In PH the excess oxalate is made by the liver rather than eaten, so researchers hoped the bacterium would draw oxalate from the blood into the gut, where it could be broken down, and so lower the amount reaching the kidneys in urine (Milliner 2018).

Getting it into the gut works. Stool counts of the bacterium rose significantly on treatment in an 8-week trial (p < 0.001) (Hoppe 2017), and it was established in the gut of treated patients after 52 weeks (Ariceta 2023). In an early 4-week pilot, by contrast, stool levels dropped as soon as dosing stopped, indicating only transient colonisation (Hoppe 2006).

Colonising the gut did not translate into lower oxalate in the controlled trials (Hoppe 2017; Milliner 2018). A 2025 systematic review of probiotic trials for kidney stones reached the same conclusion: successful colonisation with O. formigenes did not bring meaningful biochemical improvements (Bhardwaj 2025).

A 2026 review suggested why: across trials, probiotic success with oxalate depended less on dose, strain or persistence than on ecological context, especially how many oxalate-degrading genes a person's own gut microbes already carry, and efficacy was highest when that niche was vacant (Suryavanshi 2026). That idea is untested as a way to pick patients. A rising stool count is a laboratory marker, not evidence that kidneys are protected.

There is no established probiotic dose for PH. Every placebo-controlled trial used a formulation of Oxabact, tested as an investigational product in phase 1 to 3 trials. In the 52-week trial, patients took one enteric-coated capsule of freeze-dried O. formigenes strain HC-1, containing at least a billion colony-forming units, twice daily with breakfast and dinner (Ariceta 2023). It still did not lower plasma oxalate significantly more than placebo.

Probiotics sold as supplements mostly contain Lactobacillus and Bifidobacterium species, and a result for one microbe doesn't necessarily apply to another (NCCIH). We found no trial of these in people with PH. For lactic acid bacteria in ordinary stone formers, see probiotics for kidney stones.

In 42 people with PH older than 5 years with a GFR above 50 mL/min, 24 weeks of Oxabact did not change urinary oxalate more than placebo: the change was under 20% and not different between groups (P = 0.616). An ad hoc analysis of 37 compliant patients found the oxalate-to-creatinine ratio fell 21% on Oxabact and 7% on placebo, still short of significance (P = 0.06) (Hoppe 2011). In an 8-week trial in 28 patients, neither urinary nor plasma oxalate changed differently from placebo (plasma, p = 0.438), and a post hoc analysis found urinary oxalate per creatinine actually rose on treatment (Hoppe 2017).

A 24-week trial in 36 patients found no difference from placebo in urinary oxalate, plasma oxalate, stone events or the number of responders (Milliner 2018). The longest, ePHex, randomised 25 patients aged 2 or older with reduced kidney function (eGFR below 90 mL/min/1.73 m2) for 52 weeks. The treatment difference in plasma oxalate was -3.80 µmol/L (95% CI -7.83 to 0.23; p = 0.064), not significant, and kidney function stayed stable in both groups. Adjudicated kidney stone events were 7 in 13 patients on Oxabact and 8 in 12 on placebo (p = 0.12) (Ariceta 2023).

In the 24-week trial, kidney function (eGFR) fell less on Oxabact than on placebo (a change of -2.71 vs -8.00; p = 0.01), and in people with eGFR below 90, plasma oxalate rose 3.25 µmol/L on placebo and fell 1.7 µmol/L on treatment (p = 0.13) (Milliner 2018). These were secondary results in a trial whose primary outcome was null, and the later 52-week trial found kidney function stable in both groups (Ariceta 2023).

In an open-label study of people with PH type 1 on dialysis, 12 started and 8 continued; after 24 months all had reduced or non-elevated plasma oxalate compared with baseline, set against an untreated group drawn from past medical records rather than a placebo (Hoppe 2021). An early 4-week pilot without a control group reported 22-48% falls in urinary oxalate in 3 of 5 patients with normal kidney function on a paste form, and 38.5-92% falls in 4 of 6 on capsules (Hoppe 2006). Neither design can separate the bacterium's effect from chance or other care.

A 2025 meta-analysis of five randomised trials with 208 patients found no effect on plasma oxalate (P = 0.06) or urinary oxalate (mean difference -0.01 mmol/day; 95% CI -0.12 to 0.10; P = 0.86), with no excess of adverse events; the authors concluded O. formigenes was ineffective but called for more rigorous trials (Khan 2025).

No trial has been long enough to show whether a probiotic changes kidney failure or systemic oxalosis. All the placebo-controlled trials tested formulations of one company's product, and the 52-week trial was designed, funded and managed by that company (Ariceta 2023). Meanwhile, newer drugs have strong randomised evidence: in PH type 1, 84% of patients on lumasiran reached normal or near-normal urinary oxalate at 6 months versus 0% on placebo (Garrelfs 2021), and 50% on nedosiran did so on at least two consecutive visits versus 0% on placebo in PH1 and PH2 combined, with the effect seen in PH1 and no consistent effect in PH2 (Baum 2023).

Oxabact was well tolerated in the trials: no serious adverse events were reported in the first placebo-controlled trial (Hoppe 2011), no safety issues in the 8-week trial (Hoppe 2017), and in the 52-week trial there were fewer adverse events on Oxabact (46 in 13 patients) than on placebo (61 in 11 patients) (Ariceta 2023). Pooled across five trials, adverse events were not more common than on placebo (odds ratio 0.44; 95% CI 0.14 to 1.39) (Khan 2025).

Shop probiotics are a different matter. They have a long history of apparently safe use in healthy people, but few studies have examined their safety in detail; the risk of harm is greater in people with severe illness or a weakened immune system, the FDA has warned about severe infections in premature infants given probiotics, and some products contain microbes not listed on the label (NCCIH). That matters in PH because many patients eventually need a kidney or liver transplant (Michael 2024), with the necessary immunosuppression and its long-term risks (Gupta 2022).

Interactions between probiotics and medicines have been little studied (NCCIH). The practical issues are antibiotics, which can kill swallowed bacteria (the 52-week trial excluded people needing ongoing antibiotics to which O. formigenes is sensitive) (Ariceta 2023), immunosuppressants, which raise infection risk (NCCIH), and the risk of putting off proven care: NCCIH advises not using probiotics as a reason to postpone seeing a health care provider.